Respond With the Only FDA-Approved Antidote for Both Suspected or Known Cyanide Poisoning

Clinical Study Experience1

  • A controlled animal study demonstrated efficacy of hydroxocobalamin in cyanide-poisoned adult dogs; due to ethical considerations, no controlled human efficacy studies have been performed1,5
  • In an uncontrolled, open-label, prospective study, empiric administration of hydroxocobalamin was associated with survival among 67% of patients confirmed a posteriori to have had cyanide (CN) poisoning4
    • The most common hydroxocobalamin-related adverse events were chromaturia, red skin discoloration, hypertension, erythema, and increased blood pressure1,4
  • It has been shown that the concentration of blood lactate increases proportionally with the severity of CN poisoning, and that hydroxocobalamin treatment results in rapid resolution of CN-induced lactic acidemia6-8

Safety Information and Adverse Events

  • Use caution in the management of patients with known anaphylactic reactions to hydroxocobalamin or cyanocobalamin
  • Allergic reactions may include: anaphylaxis, chest tightness, edema, urticaria, pruritus, dyspnea, rash, and angioneurotic edema
  • Substantial increases in blood pressure may occur following CYANOKIT® therapy. Usage may interfere with some clinical laboratory evaluations

Single-Vial CYANOKIT®: Designed for Use at the Scene or in the Hospital

  • Full starting dose in a single vial
  • Prepare and administer in 3 steps
  • Portable packaging

For medical questions concerning CYANOKIT®, please call 1-800-438-1985, Monday through Friday, 8:00 AM to 8:00 PM ET.
To report an adverse event, or speak to a member of Pfizer US Medical Information, call 1-800-438-1985.


Indication
CYANOKIT® (hydroxocobalamin for injection) 5 g for intravenous infusion is indicated for the treatment of known or suspected cyanide poisoning. If clinical suspicion of cyanide poisoning is high, CYANOKIT® should be administered without delay.

Important Safety Information
Cyanide poisoning may result from inhalation, ingestion, or dermal exposure. Prior to administration of CYANOKIT®, smoke-inhalation victims should be assessed for: exposure to fire or smoke in an enclosed area; presence of soot around the mouth, nose, or oropharynx, and altered mental status. In addition to CYANOKIT®, treatment of cyanide poisoning must include immediate attention to airway patency, adequacy of oxygenation and hydration, cardiovascular support, and management of any seizure activity.

Use caution in the management of patients with known anaphylactic reactions to hydroxocobalamin or cyanocobalamin. Allergic reactions may include: anaphylaxis, chest tightness, edema, urticaria, pruritus, dyspnea, rash, and angioneurotic edema. Substantial increases in blood pressure may occur following CYANOKIT® therapy. Usage may interfere with some clinical laboratory evaluations. Also, because of its deep red color, hydroxocobalamin may cause hemodialysis machines to shut down due to an erroneous detection of a "blood leak." This should be considered before hemodialysis is initiated in patients treated with hydroxocobalamin. Due to potential photosensitivity, patients should avoid direct sun until erythema resolves.

CYANOKIT® is Pregnancy Category C and should be used during pregnancy only if the potential benefit justifies the potential risk. Safety and effectiveness of CYANOKIT® have not been established in pediatric patients. The most common adverse reactions (>5%) are transient and include chromaturia, erythema, rash (predominantly acneiform), increased blood pressure, nausea, headache, decreased lymphocyte percentage, and injection site reactions.

Please see single 5-g vial full Prescribing Information. Please see two 2.5-g vial full Prescribing Information.

DISCLAIMER
This Web site is intended only for First Responders and Healthcare Professionals and is subject to all applicable US laws. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.